Pyridazinone compounds and their use as DAAO inhibitors
AssigneeTakeda Pharmaceutical Company Limited
InventorsWilliam Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Claims10
A method of treating at least one symptom or condition associated with schizophrenia in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound that is 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one or a pharmaceutically acceptable salt thereof to the patient, wherein the compound is in crystalline form.
A method of treating at least one symptom or condition associated with schizophrenia in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound that is 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one or a pharmaceutically acceptable salt thereof to the patient, wherein the compound is in crystalline form and further wherein the compound is obtained by a method comprising recrystallizing 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one and/or one or more pharmaceutically acceptable salts thereof from a mixture comprising heptane and ethyl acetate.
A method of treating cognitive impairment associated with schizophrenia in a patient in need thereof, the method comprising administering a therapeutically effective amount of 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one to the patient.
A method of treating cognitive impairment associated with schizophrenia in a patient in need thereof, the method comprising administering a therapeutically effective amount of 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one or a pharmaceutically acceptable salt thereof to the patient.
Dependencies are inferred from the claim text.